

## SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) <b>PRIVACY</b>	1a. COUNTRY <b>COSTA RICA</b>	2. DATE OF BIRTH Day Month Year <b>PRIVACY</b>	2a. AGE <b>33</b> Years	3. SEX <b>Female</b>	3a. WEIGHT <b>60.20</b> kg	4-6 REACTION ONSET Day Month Year <b>MAY 2025</b>	8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) <b>hypoglycemias [Hypoglycaemia] Hyperglycemias [Hyperglycaemia]</b>  Case Description: ***This is an auto generated narrative***  Study ID: 199-NovoDia  Study description: Trial Title: Patient support programme to support physician and their daily work to maintain an optimal diabetic control of patients through added value services such as treatment starter kit, (Continued on Additional Information Page)							

## II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) <b>#1 ) IDeg PDS290 (Insulin Degludec 100 U/mL) Solution for injection, 100 U/mL #2 ) NovoRapid FlexPen (Insulin Aspart 100 U/mL) Solution for injection, 100 U/mL</b>	20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) <b>#1 ) 17 IU, qd #2 ) 10 IU, tid</b>	16. ROUTE(S) OF ADMINISTRATION <b>#1 ) Subcutaneous #2 ) Unknown</b>
17. INDICATION(S) FOR USE <b>#1 ) Type 1 diabetes mellitus (Type 1 diabetes mellitus) #2 ) Type 1 diabetes mellitus (Type 1 diabetes mellitus)</b>	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) <b>#1 ) 05-MAY-2025 / Ongoing #2 ) 2024 / Ongoing</b>	19. THERAPY DURATION <b>#1 ) Unknown #2 ) Unknown</b>

## III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates <b>Unknown to Ongoing</b>	Type of History / Notes <b>Current Condition Duration not reported</b>	Description <b>Obesity (Obesity)</b>
<b>Unknown to Ongoing</b>	<b>Current Condition Duration not reported</b>	<b>Type 1 diabetes mellitus (Type 1 diabetes mellitus)</b>

## IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER <b>Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888</b>		26. REMARKS <b>Medically Confirmed: No</b>
	24b. MFR CONTROL NO. <b>1449454</b>	25b. NAME AND ADDRESS OF REPORTER <b>NAME AND ADDRESS WITHHELD.</b>
24c. DATE RECEIVED BY MANUFACTURER <b>30-MAY-2025</b>	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT <b>04-JUL-2025</b>	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

04-Jul-2025 07:40

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

nutrition support through NovoDia call center, individual workshops, group workshops and free A1c test.

Patient's height: 160 cm.

Patient's weight: 60.2 kg.

Patient's BMI: 23.515625.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "hypoglycemias(Hypoglycemia)" beginning on MAY-2025 , "Hyperglycemias(Hyperglycemia)" beginning on MAY-2025 and concerned a 33 Years old Female patient who was treated with IDeg PDS290 (Insulin Degludec 100 U/mL) from 05-MAY-2025 and ongoing for "Type 1 diabetes mellitus" , , NovoRapid FlexPen (Insulin Aspart 100 U/mL) from 2024 and ongoing for "Type 1 diabetes mellitus",

Dosage Regimens:

IDeg PDS290: 05-MAY-2025 to Not Reported (Dosage Regimen Ongoing);

NovoRapid FlexPen: ??-???-2024 to Not Reported (Dosage Regimen Ongoing);

Current Condition: Obesity, type 1 diabetes mellitus.

Lab Data included:

Test Date: MAY-2025

Lab Data Test as Reported: Blood glucose

Test Name: Blood glucose

Results: 398

Unit: mg/dL

Test Date: MAY-2025

Lab Data Test as Reported: Blood glucose

Test Name: Blood glucose

Results: 429

Unit: mg/dL

Test Date: MAY-2025

Lab Data Test as Reported: Blood glucose

Test Name: Blood glucose

Results: 45

Unit: mg/dL

Test Date: MAY-2025

Lab Data Test as Reported: Blood glucose

Test Name: Blood glucose

Results: 49

Unit: mg/dL

Test Date: MAY-2025

Lab Data Test as Reported: Blood glucose

Test Name: Blood glucose

Results: 52

Unit: mg/dL

Batch Numbers:

IDeg PDS290: UNK;

NovoRapid FlexPen: UNK;

Action taken to IDeg PDS290 was reported as No Change.

Action taken to NovoRapid FlexPen was reported as No Change.

On MAY-2025 the outcome for the event "hypoglycemias(Hypoglycemia)" was Recovered.

04-Jul-2025 07:40

---

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

On MAY-2025 the outcome for the event "Hyperglycemias(Hyperglycemia)" was Recovered.

Reporter's causality (IDeg PDS290) -

hypoglycemias(Hypoglycemia) : Unlikely

Hyperglycemias(Hyperglycemia) : Unlikely

Company's causality (IDeg PDS290) -

hypoglycemias(Hypoglycemia) : Possible

Hyperglycemias(Hyperglycemia) : Unlikely

Reporter's causality (NovoRapid FlexPen) -

hypoglycemias(Hypoglycemia) : Unlikely

Hyperglycemias(Hyperglycemia) : Unlikely

Company's causality (NovoRapid FlexPen) -

hypoglycemias(Hypoglycemia) : Possible

Hyperglycemias(Hyperglycemia) : Unlikely

**13. Lab Data**

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1	MAY-2025	Blood glucose	429 mg/dL	
2	MAY-2025	Blood glucose	398 mg/dL	
3	MAY-2025	Blood glucose	49 mg/dL	
4	MAY-2025	Blood glucose	52 mg/dL	
5	MAY-2025	Blood glucose	45 mg/dL	